Sex and gender affect almost every aspect of #heartfailure. However, heart failure treatment is limited by a profound underrepresentation of women in clinical trials, which has resulted in a lesser understanding of disease behavior in female patients and in treatment guidelines that are predominantly based on male-derived data. Consequently, large knowledge gaps persist in sex-specific disease mechanisms, optimal drug doses for women, and sex-specific criteria for advanced heart failure therapy. Such knowledge gaps can only be closed with a systematic approach to ensure that sex-specific analyses are considered in study design, trial recruitment, statistical analysis plan, and reporting. Read more here.